The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
As September concludes, the panorama of hematologic oncology continues to evolve, spanning the total spectrum of blood most cancers care. Latest scientific...
The U.S. Meals and Drug Administration (FDA) has accepted its Guardant360® CDx as a companion diagnostic to establish sufferers with superior breast most...
